Opioid Prescribing to US Children and Young Adults in 2019
Recent national data are lacking on the prevalence, safety, and prescribers of opioid prescriptions dispensed to children and young adults aged 0 to 21 years. More
Use of term ‘low value’ may leave Black, Latinx patients with questions about access to care
This is the second of two articles on reframing the debate about low-benefit treatments. More
Are Robotic Surgeries Really Better?
Robot-assisted surgeries have only modest advantages over other approaches, a large analysis found. More
Evaluation of the Merit-Based Incentive Payment System and Surgeons Caring for Patients at High Social Risk
This cohort study evaluates the Merit-Based Incentive Payment System scoring of surgeons caring for patients at high social risk to assess whether this implementation is associated with patient access to surgical care. More
Private Equity and Health Care Delivery: Value-Based Payment as a Guardrail?
This Viewpoint considers how payment models may dictate the nature of private equity investment in health care delivery and how these investments may affect health care access, quality, equity, and affordability. More
Effort to Limit Unnecessary C-Sections Making Strides
Cesarean section births can have dangerous complications such as hemorrhaging. More
Recent studies in antibiotic stewardship
A single-center study of terminal cancer patients found a high rate of antibiotic use within the last 30 days of life, with significantly lower use among those who asked for limited antimicrobial treatment, researchers reported yesterday in Open Forum Infectious Diseases. More
The COVID-19 Pandemic and Drug Prescribing in Ontario Nursing Homes
The pharmacoepidemiologic study by Campitelli et al examined changes in medication prescribing in nursing homes in Ontario, Canada, during the first wave of the COVID-19 pandemic. More
The Question Medical AI Can’t Answer
It’s unable to tell us why it came to a particular decision—and that’s crucial information More
Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits
The 15-to-0 vote on the Alzheimer's drug Aduhelm amounted to a rebuke of both Biogen and the Food and Drug Administration. More